Company NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for NovoCure Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Equipment

Real-time Estimate Cboe BZX Other stock markets 20:51:45 29/04/2024 BST			5-day change	1st Jan Change
12.88 ^USD	+1.90%		+8.41%	-14.10%

04-24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Number of employees: 1,453

USD in Million	2022	Weight	2023	Weight	Delta
Tumor Treating Fields 100.0 %	538	100.0 %	509	100.0 %	-5.30%

USD in Million	2022	Weight	2023	Weight	Delta
United States 68.7 %	407	75.7 %	350	68.7 %	-14.05%
Germany 11.8 %	46	8.6 %	60	11.8 %	+30.55%
Others 8.7 %	0	0.0 %	44	8.7 %	-
Japan 6.2 %	33	6.1 %	32	6.2 %	-3.40%
Greater China 4.6 %	21	4.0 %	23	4.6 %	+8.87%

Managers	Title	Age	Since
Asaf Danziger CEO	Chief Executive Officer	56	31/12/01
Ashley Cordova DFI	Director of Finance/CFO	45	31/05/14
Moshe Giladi CTO	Chief Tech/Sci/R&D Officer	-	-
Nicolas Leupin CTO	Chief Tech/Sci/R&D Officer	50	01-03
Wilhelmus Groenhuysen COO	Chief Operating Officer	66	04/01/12
Ingrid Goldberg IRC	Investor Relations Contact	-	30/06/21
Barak Ben Arye LAW	General Counsel	48	31/12/17
Gabrielle Fernandes PRN	Corporate Officer/Principal	-	-
Uri Weinberg PRN	Corporate Officer/Principal	46	29/02/08
Michael Puri HRO	Human Resources Officer	55	31/08/23

Members of the board	Title	Age	Since
Bill Doyle CHM	Chairman	61	31/12/03
Kin Yip Leung BRD	Director/Board Member	62	04/08/11
David Hung BRD	Director/Board Member	66	30/05/18
Timothy Scannell BRD	Director/Board Member	60	04/02/21
Jeryl Hilleman BRD	Director/Board Member	66	24/07/18
Tony Vernon BRD	Director/Board Member	68	31/12/05
Asaf Danziger CEO	Chief Executive Officer	56	31/12/01
Martin Madden BRD	Director/Board Member	64	09/05/17
Kristin Stafford BRD	Director/Board Member	42	27/03/23
Allyson Ocean BRD	Director/Board Member	52	22/02/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	107,606,309	97,642,935 ( 90.74 %)	0	90.74 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.91 %	15,962,767	14.91 %	249 M $
Vanguard Fiduciary Trust Co. 9.113 %	9,759,098	9.113 %	153 M $
Capital Research & Management Co. (International Investors) 8.275 %	8,861,871	8.275 %	139 M $
Hansjörg Wyss 7.602 %	8,141,397	7.602 %	127 M $
BlackRock Advisors LLC 6.868 %	7,355,376	6.868 %	115 M $
Baillie Gifford & Co. 4.520 %	4,840,141	4.520 %	76 M $
STATE STREET CORPORATION 3.608 %	3,863,549	3.608 %	60 M $
Capital Research & Management Co. (World Investors) 3.060 %	3,276,996	3.060 %	51 M $
T. Rowe Price International Ltd. 2.104 %	2,253,225	2.104 %	35 M $
Two Sigma Advisers LP 1.526 %	1,634,500	1.526 %	26 M $

NovoCure Ltd.

No. 4 The Forum Grenville Street

JE2 4UF, St. Helier

+44 15 3475 6700

http://www.novocure.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.64 USD

Average target price

26.17 USD

Spread / Average Target

+107.10%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Medical Equipment

	1st Jan change	Capi.
NOVOCURE LIMITED	-14.10%	1.36B
SHOCKWAVE MEDICAL, INC.	+73.02%	12.38B
PENUMBRA, INC.	-20.18%	7.92B
MASIMO CORPORATION	+15.76%	7.2B
GETINGE AB	+6.78%	5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+7.49%	5.07B
APT MEDICAL INC.	+23.97%	4.53B
ASAHI INTECC CO., LTD.	-21.67%	3.88B
INARI MEDICAL, INC.	-40.88%	2.23B
SKAN GROUP AG	+1.24%	2.02B

Medical Equipment